Purpose: To determine the efficacy of repeat selective laser trabeculoplasty (SLT) in medication-naïve open angle glaucoma 35 (OAG) and ocular hypertensive (OHT) patients requiring repeat treatment for early to medium-term failure during the Laser in 36 Glaucoma and Ocular Hypertension (LiGHT) trial.
(available at www.aaojournal.org) INTRODUCTION cause of blindness worldwide, second only to cataract (1). The mainstay of glaucoma treatment is lowering of intraocular METHODS
94
The study was conducted in accordance to good clinical practice (GCP) guidelines and adhered to the tenets of the Declaration 95 of Helsinki. Institutional Review Board (IRB)/Ethics Committee approval was obtained. All patients provided written informed 96 consent before participation to the trial. The LiGHT Trial is registered at www.controlled-trials.com (registration number 97 ISRCTN32038223).
99
This study was a post hoc analysis of the LiGHT trial, the design and baseline characteristics of which have been previously 100 described (20, 21) . Inclusion criteria were newly diagnosed, untreated OAG or OHT in one or both eyes, qualifying for treatment 101 according to National Institute for Health and Care Excellence (NICE) guidelines (22) , open angles on gonioscopy, and, for OAG, 102 visual field loss with mean deviation (VF MD) not worse than -12 dB in the better eye or -15 dB in the worse eye and 103 corresponding damage to the optic nerve head. Patients were 18 years or older and able to read and understand English, had a 104 visual acuity of 6/36 or better in the treated eye(s) and no prior intraocular surgery, except uncomplicated phacoemulsification 105 at least one year before entering the trial.
107
Patients were excluded if there were any relative contra-indications to SLT (history of uveitis, macular oedema, secondary 108 glaucomas), if they were unable to use topical medical therapy, had symptomatic cataract and wanted to undergo cataract 109 surgery, or were having active treatment for another ophthalmic condition. All measurements influencing treatment escalation 110 decisions were performed by masked observers: automated visual field using Humphrey Field Analyzer Mark II Swedish 111 interactive threshold algorithm standard 24-2 programme (Carl Zeiss Meditec, Dublin, CA, USA), Heidelberg Retina Tomography 112 (HRT) disc imaging (Heidelberg Engineering, Heidelberg, Germany) and IOP (Goldmann applanation tonometry with daily 113 calibration). Clinicians and patients were not masked to treatment allocation. Patients were monitored for 3 years in this initial 114 phase of the study.
116
Glaucoma severity was defined (see Table 1 ) with pre-set objective severity criteria from the Canadian Target IOP Workshop (23) 117 with additional central VF loss criteria (24). Severity stratification (OHT, mild, moderate or more severe OAG) determined an eye 118 specific 'Treatment Target IOP' and follow-up intervals. Target IOP was objectively defined based on both percentage reduction 119 from untreated IOP and an absolute value and then adjusted during the study according to presence or absence of disease 120 progression.
122
To minimise bias in escalating treatment, standardised criteria were used according to a protocol following the international 123 guidelines of the European Glaucoma Society, (25) American Academy of Ophthalmology Preferred Practice Pattern (26) 
137
Target IOP was reduced by 20% if deterioration was identified despite the measured IOP being at or below target. If the IOP was 138 above target by less than 4mmHg, but with no evidence for deterioration, then the target IOP was revised to the mean of the 139 previous 3 visits over which deterioration had not occurred. The process for escalating treatment is shown in Figure 1 .
141
Follow-up intervals were initially set at entry to the study according to NICE guidance (22) and subsequently adjusted on the 142 basis of IOP control, glaucoma progression status or adverse reactions. The routine schedule of appointments and assessments 143 for patients has been published previously (21) . At follow up, patients underwent visual acuity testing (ETDRS logMAR at a 144 starting distance of 4 m), slit-lamp examination, visual field testing, HRT optic disc imaging, single IOP measurement (Goldmann 145 applanation tonometry) and clinical assessment of the optic discs, maculae and fundi.
147
Standardisation of SLT delivery was achieved by protocol-defined settings and clinical endpoints. The protocol defined 360-148 degree TM treatment, delivered by 100 non-overlapping shots (25 per quadrant) of a preset 3 nanoseconds duration and preset 149 400μm spot size, with the laser energy from 0.3 to 1.9mJ set by the clinician according to observable bubble formation at least 150 50% of the time. IOP was checked 60 minutes following SLT procedure. One SLT re-treatment was permitted during the study, 151 if/when a treatment escalation was recommended by the decision support software (using criteria for treatment escalation 152 described above) and confirmed by the treating clinician. To allow time for the full effects of laser to occur, the earliest interval 153 at which Repeat SLT was permitted was following the first scheduled visit 2 months post Initial SLT. SLT was not repeated if 154 significant complications of laser treatment had occurred (one patient with IOP spike), if new medical conditions prevented 155 repetition or patients declined re-treatment (usually due to a lack of IOP lowering response following Initial SLT -not protocol defined). In such cases, treatment escalation with topical medication rather than Repeat SLT was permitted. In eyes that underwent Repeat SLT, if further treatment escalation was later required, then topical medication was the next step.
159
All eligible study eyes that received 2 SLTs within the first 18 months of the LiGHT trial were included in the analysis, such that 160 eyes had at least as long a duration of follow up after initial and Repeat SLT. For Initial SLT, baseline IOP was the pretreatment 161 IOP measured on the date of the patient's baseline visit. For Repeat SLT, pre-retreatment IOP was the IOP at the clinical visit at 162 which the decision support software recommended a treatment escalation (as confirmed by the treating clinician and when the 163 decision to escalate treatment was made). When eyes received retreatment, IOP values at time points subsequent to Repeat SLT 164 laser were not included as part of Initial SLT values but as the part of "Repeat SLT". Similarly, for eyes started on topical 165 medication following "Repeat SLT", IOP at time points subsequent to initiation of medication were not included as part of 166 "Repeat SLT", since these were a reflection of SLT and medication combined and not SLT efficacy alone.
168
We present IOP at post-laser time points (2 months, 6 months, 12 months and 18 months). To demonstrate the IOP lowering 169 efficacy of initial and Repeat SLT in this cohort of eyes receiving Repeat SLT due to early/medium-term failure, we focussed 170 primarily on the 2-month timepoint. This was the first scheduled visit following laser, allowing time for the full laser effect to 171 occur, whilst also being free from bias arising from censoring of IOP data due to introduction of additional treatment at later 172 timepoints ('treatment escalations'). Previous analysis of all subjects in the SLT arm has showed 2-month IOP response to be a 173 strong predictor of 3 year outcomes and an indicator of future control (28) .
175
We evaluted whether the treatment response of Initial SLT influenced the efficacy of Repeat SLT in this cohort of early/medium-176 term SLT failures receiving repeat treatment. We compared IOP lowering between eyes that demonstrated an initial (but 177 insufficient) IOP-lowering response following Initial SLT ('Early Failures': Repeat SLT required following the first scheduled visit at 
189
The unit of analysis was the eye. All eligible study eyes that received 2 SLTs within the first 18 months of the LiGHT trial were 190 included in the analysis, with appropriate statistical measures taken to account for correlation amongst paired eyes within a 191 patient.
193
Mean IOP at 2 months (following initial and Repeat SLT) was compared with respective pretreatment IOPs using mixed model 194 analysis with crossed random effects. Random effects were used to adjust for correlation between paired eyes whilst also taking 195 into account repeated measures within eyes. Mixed model analysis with crossed random effects was also used for comparison 196 of absolute IOP reduction and adjusted absolute IOP reduction between initial and Repeat SLT at 2 months, and for comparison 197 of absolute IOP lowering for Repeat SLT in 'early failures' vs 'later failure' eyes.
199
Statistical comparisons were made at baseline and the 2-month timepoint, but beyond 2 months, eyes were censored if they 200 underwent treatment escalation and so statistical comparison of IOP reduction between initial vs Repeat SLT at further 201 timepoints was not performed.
203
A sensitivity analysis using one eye chosen at random per patient (for subjects with both eyes in the original analysis) was also 204 performed. A Kaplan Meier plot was also produced using one eye chosen at random (for subjects with both eyes in the original 
214
Additionally, 43 eyes had been started on topical medication following Initial SLT (and did not undergo Repeat SLT). 20 of these 215 eyes were started on topical medication following the first scheduled visit at 2 months and were judged by treating clinicians to 216 have had 'no' treatment effect from Initial SLT. A further 23 eyes were started on topical medication beyond the first scheduled 217 visit and did not undergo Repeat SLT. The decision to start medication instead of Repeat SLT in these 23 eyes was made jointly 218 by the local treating clinician and patients. At 18 months, 453 eyes were still successfully maintaining IOP control following 219 single, initial baseline SLT and had not required additional treatment.
The demographics of the 90 patients with the study sample of 115 eyes are presented in Table 2 . The distribution of glaucoma 223 severities was similar in the sensitivity analysis using one eye randomly selected per patient (see Appendix).
225 IOP LOWERING EFFICACY OF INITIAL AND REPEAT SLT

227 228
Mean IOP values at each post laser time point for initial and Repeat SLT are given in Table 3 . Pre-treatment IOP prior to Initial
229
SLT was significantly higher than the pre-retreatment IOP prior to Repeat SLT (mean difference: 3.4mmHg, 95% CI, 2.6 to 230 4.3mmHg; p<0.001). Comparison of absolute IOP reduction at 2-months between initial and repeat SLT demonstrated a greater 231 reduction following initial SLT which was statistically, and probably clinically, significant (mean difference: 1.0, 95% CI 0.2 to 1.8, 232 mmHg; p=0.02). Adjusting for the corresponding pre-treatment IOP ('adjusted absolute IOP reduction'), the adjusted absolute 233 IOP reduction at 2-months was greater following Repeat SLT (adjusted mean difference: -1.1, 95% CI -1.7 to -0.5, mmHg; 234 p=0.001). Sensitivity analysis using one eye randomly selected per patient also demonstrated similar results (see Appendix).
235
Beyond 2 months, eyes were censored if they underwent treatment escalation and so statistical comparison of IOP reduction 236 between Initial vs Repeat SLT was not performed.
238
Mean (SD) total power of Initial SLT was 89.1mJ (27.5) and total number of applications was 98.9 (4.6) shots. Mean (SD) total 239 power of Repeat SLT was 100.5mJ (24.9) and total number of applications was 99.5 (4.6) shots. The difference in total power of 240 SLT between Initial vs Repeat SLT was both clinically and statistically significant (mean difference: 11.6mJ, 95% CI 7.7mJ to 241 15.6mJ; p<0.001). There was no significant difference in the total number of applications (mean difference: 0.6 shots, -0.5 shots 242 to 1.7 shots; p=0.266). 243 244 245 246 Repeat SLT at 2 months ('Early Failures') vs 81 eyes required Repeat SLT later ('Later Failures). IOP lowering data at 2 months for 248 'Early' and 'Later' Failures is presented, alongside for reference, the 2 month IOP lowering data for the 43 eyes started on topical 249 medication following initial SLT and the 453 eyes that were maintaining successful IOP control following initial SLT.
251
Overall, in both the 'Early Failures' and 'Late Failures' Repeat SLT eyes, there was a greater proportion of eyes with 'moderate' 252 and 'severe' POAG compared to the group of eyes controlled on a single SLT at 18 months. They also had a greater required 253 absolute IOP reduction to achieve 'Target IOP' compared to eyes controlled on a single SLT at 18 months.
255
Comparison of pre-treatment IOP prior to initial SLT for the 'Early Failures' vs 'Later Failures' who underwent repeat SLT 256 demonstrated a significantly higher pre-treatment IOP in the 'Early Failures' eyes (mean difference: 3.0mmHg, 95% CI, 0.3 to 257 5.8mmHg; p=0.033). Absolute IOP reduction at 2 months following initial SLT was not statistically or clinically significantly 258 different between 'Early Failures' and 'Later Failures' (mean difference: 0.6 mmHg, 95% CI, -1.4 to 2.6; p=0.551). There was no 259 significant difference in pre-retreatment IOP prior to Repeat SLT between 'Early Failures' vs 'Later Failures' eyes (mean 260 difference: 1.2 mmHg, 95% CI, -0.5 to 3.0 mmHg; p=0.169), with no significant difference in absolute IOP reduction following 261 Repeat SLT at 2 months between 'Early Failures' vs 'Later Failures' (mean difference 0.3mmHg, 95% CI, -1.1 to 1.8mmHg; 262 p=0.655).
264
For reference, mean absolute IOP reduction at 2 months following Initial SLT (95% CI) in the 20 eyes which then immediately 265 started on topical medication ('no' treatment effect from Initial SLT -as judged by clinician) was 1.3mmHg (-0.2 to 2.7mmHg).
266
Mean absolute IOP reduction (95% CI) at 2 months in the 23 eyes which started on topical medication beyond the first 267 scheduled visit but did not undergo Repeat SLT was 5.1mmHg (3.7 to 6.1mmHg). Mean absolute IOP reduction (95% CI) at 2 268 months in the 453 eyes successfully maintaining IOP control to 18 months following single Initial SLT was 7.9mmHg (7.6 to Figure 2 . We could not determine overall median duration of 277 effect for Repeat SLT, as 50% of these eyes did not reach the endpoint within the 18 months follow up period, though our results show that it is at least 18 months. Two eyes in the study sample underwent cataract surgery for visually significant cataract 279 during the study period (following Repeat SLT) and were included in this analysis. If these 2 eyes are excluded from the analysis 280 or treated as Repeat SLT failures, the results and conclusions are unchanged.
282
Thirty eight of 115 eyes (33%) receiving Repeat SLT within the first 18 months had commenced medical treatment ('Repeat SLT 283 failures') in the 18 months following the Repeat SLT. Approximately 60% of these eyes had a baseline disease severity of either 284 'moderate' OAG (12 eyes, 31.6%) or 'severe' OAG (11 eyes, 29%), with fewer OHT (1 eye, 2.6%) or 'mild' OAG (14 eyes, 36.8%).
285
In these 38 'Repeat SLT failure' eyes, 20 were 'early failures' and 18 were 'later failures' following Initial SLT.
287
The remaining 67% of eyes (77 of 115) did not require further intervention in the subsequent 18 months. Approximately 68% of 288 these eyes had a baseline disease severity of either 'OHT' (21 eyes, 27.3%) or 'mild' OAG (32 eyes, 41.6%), with fewer 289 'moderate' OAG (15 eyes, 19.5%) or 'severe' OAG (9 eyes, 11.7%). Survival estimates taking one randomly-selected eye per 290 patient were similar (see Appendix).
292
Of the 115 eyes requiring Repeat SLT following Initial SLT, the indication for Repeat SLT in 98.3% (113 eyes) of eyes 293 was due to the IOP not being at target. Of the 2 remaining eyes, 1 eye required Repeat SLT due to IOP not being at target and 294 concurrent visual field progression and the other eye due to visual field progression alone. Of the 38 eyes requiring additional 295 treatment escalation following Repeat SLT (i.e. started on medication), 92.1% (35 eyes) of these eyes were escalated due to the 296 IOP not being at target. Of the 3 remaining eyes, 1 eye required additional treatment due to the IOP not being at target and 297 concurrent visual field progression whilst 2 eyes had visual field progression alone.
299 SAFETY
300
We found no evidence of harm caused by SLT during the LiGHT trial (15, 28) ; no IOP spikes >5mmHg from pre-treatment IOP at 301 60 minutes post procedure were seen after Repeat SLT. There were no sight threatening adverse events related to initial or 302 Repeat SLT. All laser-related adverse events (e.g. discomfort, headaches, hyperaemia, transient blurred vison) were self-limiting 303 and resolved within 8 weeks following SLT.
305 DISCUSSION
307
The aim of this study was to determine and characterise the efficacy of Repeat SLT in eyes requiring retreatment (within 18 308 months) following Initial SLT. Mean IOP following both Initial and Repeat SLT was clinically and statistically significantly reduced from the corresponding pre-treatment IOP at 2 months (p<0.001), confirming Repeat SLT to be effective (see Table 3 ). This 310 supports results from other studies which have suggested effective IOP reduction following Repeat SLT (8-10, 12, 13) .
312
Furthermore, compared to Initial SLT (controlling for difference in pre-treatment IOPs), adjusted absolute IOP reduction was 313 statistically significantly greater following Repeat SLT at the 2 month timepoint than at the same time post-laser following the 314 first treatment. It is possible that this demonstrates an additive effect of Repeat SLT. An alternative explanation is that this may 315 be inflated by superimposed effects of regression to the mean: LiGHT is a pragmatic trial primarily designed to evaluate quality 316 of life and cost-effectiveness and patients were not recalled to define a second baseline IOP prior to Repeat SLT. However, the 
321
Following Initial SLT, there was a trend for mean IOP to increase over time. By the nature of the patient selection for this 322 analysis, this was more rapid than in the LiGHT trial overall (15), since we specifically selected patients requiring retreatment 323 within 18 months. Our trial protocol mandated that more advanced disease had to achieve more stringent targets with greater 324 IOP reductions (minimum 30% reduction vs minimum 20% for mild OAG or OHT eyes) (20) and were thus more likely to need 325 treatment escalation to achieve these lower targets. This is reflected in the greater proportion of 'moderate' OAG or 'severe' 326 OAG (47/115 = 40.9%) eyes in the Repeat SLT study sample compared to those eyes controlled on single SLT at 18 months 327 (44/453 = 9.7%) and the greater IOP reduction required to achieve the target IOP (Table 4) , especially in the 'early failure' group.
329
Similar to other studies (8-10, 13), the pretreatment baseline IOP of Initial SLT was significantly higher than that prior to Repeat 330 SLT (mean difference: 3.4mmHg, 95% confidence interval (CI), 2.6 to 4.3mmHg; p<0.001). This is because Repeat SLT was 331 delivered prior to the full treatment effect of the Initial SLT wearing off, in contrast to the treatment-naïve baseline IOP. This 332 mirrors clinical practice where repeat treatment escalations (medication, laser or surgery) are usually not delayed to allow IOP 333 to return to pre-treatment levels. Higher starting baseline IOP has been found to be a predictor of greater absolute IOP lowering 334 (30) and hence mean absolute IOP reduction was expected to be less for Repeat SLT compared to Initial SLT (e.g. at 2 month 335 timepoint, mean difference 1.0mmHg, 95% CI 0.2 to 1.8mmHg; p<0.001). The greater adjusted absolute IOP reduction after 336 Repeat SLT, controlling for the difference in pre-treatment IOP, suggests that further laser may be additive to the initial 337 treatment. This is also suggested by the cumulative treatment effect measured at 2 months after Repeat SLT being similar to the 338 treatment effect achieved after the Initial SLT in those not requiring re-treatment (see table 4 ). 339 340 11.6mJ, 95% CI 7.7mJ to 15.6mJ; p<0.001) whereas there was no clinically or statistically significant difference in the number of 342 applications (mean difference: 0.6 shots, -0.5 shots to 1.7 shots; p=0.266). The greater total power used for Repeat SLT could be 343 due to several reasons. Firstly, greater energy per shot may have been required during Repeat SLT to generate the 'observable 344 bubble formation at least 50% of the time' as mandated by our SLT treatment protocol. There could also have been treatment 345 bias by the clinicians who may have increased the energy per shot, having recognised that Initial SLT (with a lower total power) 346 had not been as effective as hope, by virtue of the patient receiving Repeat SLT.
348
We sought to determine whether 'early' treatment failure compared to 'later' treatment failure of Initial SLT predicted the 349 response to Repeat SLT. Our results show that Early Failures of Initial SLT had higher pre-treatment baseline IOPs and less initial 350 IOP lowering compared to Later Failures of Initial SLT, but that Repeat SLT provided a meaningful additional IOP lowering effect.
351
The greater number of 'moderate' and 'severe' OAG eyes in the Early Failure compared to Later Failure group, also meant that 352 the Early Failure group required greater absolute IOP reductions to achieve target IOP (and similarly compared to those eyes 353 controlled on a single SLT at 18 months) -see Table 4 .
355
In our Kaplan Meier analysis, we used a clinically-relevant and robust definition of success: IOP control (IOP at or below target 356 IOP) maintained after Initial SLT without additional IOP lowering medications, further laser procedures or incisional glaucoma 357 surgery (10) . The Kaplan Meier analysis shows that Repeat SLT can have a longer duration of IOP-lowering than the first laser.
358
Thus, even after a waning of effect within 18 months, repeat treatment may work for longer and thus be worthwhile. Other 359 studies have also suggested that Repeat SLT could have a longer duration of clinical benefit than Initial SLT (10, 13) . Of the eyes 360 that failed following Repeat SLT, the majority had a baseline disease severity of either 'moderate' OAG (12 eyes, 31.6%) or 361 'severe' OAG (11 eyes, 29%). This could partly explain the greater proportion of 'early failure' eyes failing Repeat SLT (20/34 = 362 58.8%) compared to 'later failures' (18/81 = 22.2%) as the increased relative proportion of 'moderate' and 'severe' OAG eyes 363 compared to 'later failures' necessitated a greater absolute IOP reduction to achieve target IOP.
365
Direct comparison of our results with other studies is difficult due to differences in study design, patient demographics and 366 concurrent use of topical medication at the time of SLT. However, mean absolute IOP reduction in our study for both initial and
367
Repeat SLT was comparable with what has been previously reported (9, 10, 13, 14) . Where variations exist, this could be due to 368 higher baseline IOPs (for both Initial and Repeat SLT) in our study, since eyes in our analysis were not on concurrent topical 369 medication at the time of either Initial or Repeat SLT in contrast to other studies (8-10, 12, 14) . Differences in SLT treatment 370 protocol such as number of spots and degree of TM treated could also be contributory (13) . In our study, we also escalated 371 treatment when patients failed to reach pre-defined indvidualised target IOPs following both Initial and Repeat SLT; thus there are fewer eyes available for analysis at later time-points due to censoring of IOP data from medication-treated eyes, which 373 means we should be cautious interpreting mean IOP outcomes beyond 2 months.
375
Certain other cautions should be noted. There is a selection bias in several of the retrospective SLT repeatability studies and 376 also in our study, where eyes included were those having Repeat SLT following an initial response to the first SLT (judged by the 377 treating clinician). During the LiGHT trial, by 18 months, 43 eyes out of original 611 eyes treated with SLT (7.0%) had been 378 started on topical medication following Initial SLT rather than receiving Repeat SLT. Twenty of these eyes were started on topical 379 medication following the first scheduled visit at 2 months and were judged by treating clinicians to have had 'no' treatment 380 effect from Initial SLT. There were also too few eyes (n=15 eyes) that underwent Repeat SLT after 'no' initial response (less than 381 a 10% change in IOP after first SLT) to be able to draw meaningful conclusions about the effects of a Repeat SLT when the first 382 gave no IOP lowering response. This means we cannot comment on the overall efficacy of Repeat SLT entirely irrespective of 383 Initial SLT response from this analysis. Furthermore, our analysis comprises a sample of the original 611 eyes receiving SLT at 384 baseline who then required Repeat SLT within the first 18 months of the trial, so that duration of follow-up would be at least as 385 long (18.8%, 115 eyes). It does not include those eyes in the trial that received single SLT and subsequently maintained IOP 386 control until the end of the trial at 36 months. It is therefore important to note that the median duration of survival for Initial 387 SLT presented in this analysis is for eyes that required Repeat SLT within the first 18 months of the trial and not for all eyes 388 following Initial SLT, or for eyes that had retreatment beyond the initial 18 months of the study.
390
Compared to previous SLT repeatability studies, this study has several strengths. The LiGHT trial was multi-centre and conducted 391 prospectively. Eyes were treated to pre-defined target IOPs based on disease severity with pre-defined treatment escalation 392 criteria and SLT treatment parameters in treatment-naive subjects (20). Limitations include the post-hoc (albeit pre-specified) 393 nature of this analysis. Despite this, we present one of the largest datasets of RCT-collected clinical data on Repeat SLT in 394 treatment-naïve OAG/OHT patients. Whilst the analyses performed are exploratory, they are clinically valuable and add to the 395 body of evidence supporting the use of Repeat SLT in medication-naive eyes that have undergone previous primary SLT.
397 CONCLUSIONS
398
Analysis of Repeat SLT responses showed that it is effective at achieving IOP control in OAG and OHT eyes requiring retreatment 399 within 18 months of Initial SLT. Additional SLT maintained drop-free IOP control in 67% of eyes 18 months later. Although in this 400 study, the eyes requiring lower target IOPs would be deemed failures, the laser did contribute significantly to lowering IOPs.
401
Following Repeat SLT, the cumulative effect of initial and Repeat SLT may provide an equivalent and possibly longer duration of 402 clinical benefit than following Initial SLT alone. Repeat SLT is safe, with minimal laser-related side effects seen during the LiGHT 403 trial. a: IOP data missing: 15 eyes at 2 months, 2 eyes at 6 months, 1 eye at 12 months for Initial SLT. b: IOP data censored (no longer at target, treatment escalated): 3 eyes at 2 months, 55 eyes at 6 months, 88 eyes at 12 months, 115 eyes at 18 months for Initial SLT.
404
c: IOP data missing: 9 eyes at 2 months, 6 eyes at 6 months, 8 eyes at 12 months, 15 eyes at 18 months for Repeat SLT. d: IOP data censored (no longer at target, treatment escalated: 2 eyes at 2 months, 21 eyes at 6 months, 31 eyes at 12 months, 38 eyes at 18 months for Repeat SLT.
*Significant reduction in mean absolute IOP reduction from respective pre-treatment IOP at 2-month time point for initial and Repeat SLT (p<0.001) ** Significant difference in pre-treatment IOP between initial and Repeat SLT (mean difference: 3.4, 95% CI 2.6 to 4.3, mmHg; p<0.001) *** Adjusted analysis of absolute IOP reduction from pre-treatment IOP (adjusting for corresponding pre-treatment IOP) Table 4 : Early IOP lowering of Eyes following Initial SLT and Repeat SLT 
*Difference between 'Early failures' vs 'Later failures' who underwent repeat SLT calculated using mixed model analysis with cross random effects and presented in main manuscript results
